Spinal myoclonus following intrathecal administration of diatrizoate meglumine.
Life-threatening myoclonus developed in a patient following inadvertent intrathecal usage of 60% diatrizoate meglumine. Rhabdomyolysis and myoglobinuria occurred. The patient was successfully treated with midazolam and vecuronium and complete recovery occurred.
Department of Neurology, Robert C. Byrd Health Sciences Center, West Virginia University, USA.
M C
MC
Sam
L
L
Gutmann
D000368:Aged; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D003974:Diatrizoate Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007278:Injections, Spinal; D008297:Male; D008874:Midazolam / Q000627:therapeutic use; D009207:Myoclonus / Q000139:chemically induced* / Q000188:drug therapy; D009212:Myoglobinuria / Q000139:chemically induced; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000139:chemically induced; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000188:drug therapy; D014673:Vecuronium Bromide / Q000627:therapeutic use
D003287:Contrast Media; D006993:Hypnotics and Sedatives; D003473:Neuromuscular Nondepolarizing Agents; D003974:Diatrizoate Meglumine; D014673:Vecuronium Bromide; D008874:Midazolam